Does Every Target Need the Same Radionuclide? Rethinking Isotope Selection for the Next Generation of Radiopharmaceuticals

• Discovering why radionuclide selection should be driven by target biology, tumour characteristics and pharmacokinetics rather than platform familiarity
• Examining how different isotopes may influence therapeutic index, dosimetry, manufacturability and ultimately clinical success across diverse target classes
• Sharing lessons from designing next-generation theranostic programmes where isotope selection is considered alongside target selection from the earliest stages

Speakers: